Michael Klichinsky

6.1k total citations · 1 hit paper
56 papers, 2.0k citations indexed

About

Michael Klichinsky is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael Klichinsky has authored 56 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 38 papers in Immunology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael Klichinsky's work include CAR-T cell therapy research (48 papers), Immune cells in cancer (21 papers) and Phagocytosis and Immune Regulation (14 papers). Michael Klichinsky is often cited by papers focused on CAR-T cell therapy research (48 papers), Immune cells in cancer (21 papers) and Phagocytosis and Immune Regulation (14 papers). Michael Klichinsky collaborates with scholars based in United States, Canada and Italy. Michael Klichinsky's co-authors include Saar Gill, Nicholas R. Anderson, Nicholas G. Minutolo, Olga Shestova, Saad S. Kenderian, Marco Ruella, Carl H. June, Paul M. Lieberman, Italo Tempera and John Scholler and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Klichinsky

54 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrophage-Based Approaches for Cancer Immunotherapy

2020 498 citations Saar Gill, Michael Klichinsky et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Klichinsky United States	14	1.3k	902	586	327	315	56	2.0k
Jean‐Baptiste Latouche France	20	1.6k 1.2×	1.2k 1.4×	679 1.2×	542 1.7×	301 1.0×	47	2.3k
Jennifer L. Brogdon United States	18	2.1k 1.6×	1.6k 1.8×	785 1.3×	418 1.3×	426 1.4×	30	3.2k
Jillian L. Astarita United States	12	1.2k 0.9×	1.2k 1.3×	900 1.5×	190 0.6×	206 0.7×	17	2.7k
Elena Sotillo United States	22	1.6k 1.2×	588 0.7×	980 1.7×	396 1.2×	491 1.6×	45	2.3k
Sander Kelderman Netherlands	10	1.4k 1.1×	1.2k 1.3×	526 0.9×	169 0.5×	295 0.9×	12	2.0k
Paul Zajac Switzerland	27	1.1k 0.9×	1.1k 1.3×	654 1.1×	217 0.7×	286 0.9×	57	2.4k
Susana Inogés Spain	28	1.2k 0.9×	1.8k 2.0×	912 1.6×	112 0.3×	192 0.6×	65	3.0k
Cristina Puig-Saus United States	13	1.4k 1.1×	1.0k 1.1×	704 1.2×	238 0.7×	161 0.5×	18	2.0k
Carsten Linnemann Netherlands	17	1.7k 1.3×	1.8k 2.0×	736 1.3×	316 1.0×	130 0.4×	21	2.5k
Sanja Stevanović United States	15	1.4k 1.0×	1.1k 1.3×	419 0.7×	291 0.9×	107 0.3×	31	2.1k

Countries citing papers authored by Michael Klichinsky

Since Specialization

Citations

This map shows the geographic impact of Michael Klichinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Klichinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Klichinsky more than expected).

Fields of papers citing papers by Michael Klichinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Klichinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Klichinsky. The network helps show where Michael Klichinsky may publish in the future.

Co-authorship network of co-authors of Michael Klichinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Klichinsky. A scholar is included among the top collaborators of Michael Klichinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Klichinsky. Michael Klichinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scharenberg, Andrew M., Kevin M. Friedman, Lin T. Guey, et al.. (2025). In vivo chimeric antigen receptor (CAR)-T cell therapy. Nature Reviews Drug Discovery. 25(2). 116–137. 4 indexed citations

Shi, Hongxue, Xiaobo Wang, Brennan D. Gerlach, et al.. (2025). Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis. Science Translational Medicine. 17(815). eadv2106–eadv2106. 2 indexed citations

Abdou, Yara, Paula R. Pohlmann, Richard T. Maziarz, et al.. (2024). A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2682–TPS2682. 4 indexed citations

Beghi, Silvia, Rehman Qureshi, Michael Ball, et al.. (2024). Abstract 5249: Macrophages expressing synthetic cytokine receptors reverse IL10-mediated immunosuppression within solid tumors and promote adaptive immunity. Cancer Research. 84(6_Supplement). 5249–5249. 2 indexed citations

Abdou, Yara, E. Claire Dees, Joanne Mortimer, et al.. (2023). Abstract CT241: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors. Cancer Research. 83(8_Supplement). CT241–CT241. 2 indexed citations

Reiss, Kim A., Joanne Mortimer, Paula R. Pohlmann, et al.. (2023). 635 A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. SHILAP Revista de lepidopterología. A726–A726. 1 indexed citations

Gabbasov, Rashid, Alison Worth, Michael Ball, et al.. (2022). 371 Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy. Regular and Young Investigator Award Abstracts. A390–A390. 4 indexed citations

Gill, Saar, et al.. (2021). Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Frontiers in Immunology. 12. 783305–783305. 163 indexed citations

Bauml, Joshua, et al.. (2021). Abstract CT204: A phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. Cancer Research. 81(13_Supplement). CT204–CT204. 1 indexed citations

10.

Gabitova, Linara, Rashid Gabbasov, Stefano Pierini, et al.. (2021). Abstract 1530: Anti-HER2 CAR monocytes demonstrate targeted anti-tumor activity and enable a single day cell manufacturing process. Cancer Research. 81(13_Supplement). 1530–1530. 9 indexed citations

11.

Klichinsky, Michael, Marco Ruella, Olga Shestova, et al.. (2020). Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy. Cancer Immunology Research. 8(4_Supplement). PR07–PR07. 2 indexed citations

12.

Ruella, Marco, Michael Klichinsky, Saad S. Kenderian, et al.. (2017). Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery. 7(10). 1154–1167. 153 indexed citations

13.

Klichinsky, Michael, Marco Ruella, Olga Shestova, et al.. (2017). Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors. Cancer Research. 77(13_Supplement). 4575–4575. 9 indexed citations

14.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research. 22(11). 2684–2696. 141 indexed citations

15.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. Blood. 128(22). 2159–2159. 8 indexed citations

16.

Kenderian, Saad S., Marco Ruella, Olga Shestova, et al.. (2016). Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. Blood. 128(22). 652–652. 31 indexed citations

17.

Kenderian, Saad S., Marco Ruella, Olga Shestova, et al.. (2015). CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 29(8). 1637–1647. 335 indexed citations

18.

Balenga, Nariman, Michael Klichinsky, Zhihui Xie, et al.. (2015). A fungal protease allergen provokes airway hyper-responsiveness in asthma. Nature Communications. 6(1). 6763–6763. 102 indexed citations

19.

Arvey, Aaron, Italo Tempera, Kevin Tsai, et al.. (2012). An Atlas of the Epstein-Barr Virus Transcriptome and Epigenome Reveals Host-Virus Regulatory Interactions. Cell Host & Microbe. 12(2). 233–245. 192 indexed citations

20.

Tempera, Italo, Michael Klichinsky, & Paul M. Lieberman. (2011). EBV Latency Types Adopt Alternative Chromatin Conformations. PLoS Pathogens. 7(7). e1002180–e1002180. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact